5-bromo-1H-Indazole-4-carboxylic acid | 750586-03-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-bromo-1H-Indazole-4-carboxylic acid
• CAS: 750586-03-9
• 化学式: C₈H₅BrN₂O₂
• 分子量: 241.04
• InChiKey: FLDMHXBQEUSTQR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  66
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP2098513A1

  公开（公告）日：2009-09-09

  The present invention provides a compound represented by the formula wherein R1 is a hydrocarbon group optionally having substituent(s), amino optionally having substituent(s), hydroxy optionally having a substituent or a heterocyclic group optionally having substituent(s), R2 is a hydrogen atom or a hydrocarbon group optionally having substituent(s), R3 is a hydrogen atom, a halogen atom, a hydrocarbon group optionally having substituent(s), amino optionally having substituent(s), hydroxy optionally having a substituent or mercapto optionally having a substituent, Xa, Xb, Xc and Xd are each a carbon atom or a nitrogen atom, provided that any one or two of Xa, Xb, Xc and Xd is/are nitrogen atom(s), m is 0 to 2, and rings A to C are each a ring optionally having substituent(s), or a salt thereof, which is useful as an agent for the prophylaxis or treatment of a disease relating to an action of melatonin, and the like.

  本发明提供了一种由式表示的化合物 其中 R1 是任选具有取代基的烃基、任选具有取代基的氨基、任选具有取代基的羟基或任选具有取代基的杂环基；R2 是氢原子或任选具有取代基的烃基；R3 是氢原子、卤素原子、任选具有取代基的烃基、任选具有取代基的氨基、Xa、Xb、Xc 和 Xd 各为碳原子或氮原子，条件是 Xa、Xb、Xc 和 Xd 中的任意一个或两个为氮原子，m 为 0 至 2，环 A 至 C 各为可选具有取代基的环，或其盐，可用作预防或治疗与褪黑素作用有关的疾病的制剂等。
• [EN] ESTROGEN RECEPTOR MODULATORS<br/>[FR] MODULATEURS DE RECEPTEUR D'OESTROGENES
  申请人：MERCK & CO INC

  公开号：WO2004073612A2

  公开（公告）日：2004-09-02

  The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone loss, bone fractures, osteoporosis, metastatic bone disease, Paget s disease, periodontal disease, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, cerebral degenerative disorders, restenosis, gynecomastia, vascular smooth muscle cell proliferation, obesity, incontinence, and cancer.